技术资料
-
A. G. L. D. Rorà et al. (Nov 2024) Journal of Translational Medicine 22Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions
The introduction of antibody–drug conjugates represents a significant advancement in targeted therapy of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Our study aims to investigate the role of the DNA damage response pathway and the impact of PARP1 inhibition,utilizing talazoparib,on the response of AML and ALL cells to Gemtuzumab ozogamicin (GO) and Inotuzumab ozogamicin (INO),respectively. AML and ALL cells were treated with GO,INO and γ-calicheamicin in order to induce severe DNA damage and activate the G2/M cell-cycle checkpoint in a dose- and time-dependent manner. The efficacy of PARP1 inhibitors and,in particular,talazoparib in enhancing INO or GO against ALL or AML cells was assessed through measurements of cell viability,cell death,cell cycle progression,DNA damage repair,accumulation of mitotic DNA damage and inhibition of clonogenic capacity. We observed that both ALL and AML cell lines activate the G2/M cell-cycle checkpoint in response to γ-calicheamicin-induced DNA damage,highlighting a shared cellular response mechanism. Talazoparib significantly enhanced the efficacy of INO against ALL cell lines,resulting in reduced cell viability,increased cell death,G2/M cell-cycle checkpoint override,accumulation of mitotic DNA damage and inhibition of clonogenic capacity. Strong synergism was observed in primary ALL cells treated with the combination. In contrast,AML cells exhibited a heterogeneous response to talazoparib in combination with GO. Our findings suggest a potential link between the differential responses of ALL and AML cells to the drug combinations and the ability of talazoparibto override G2/M cell-cycle arrest induced by antibody–drug conjugates. PARP1 emerges as a key player in the response of ALL cells to INO and represents a promising target for therapeutic intervention in this leukemia setting. Our study sheds light on the intricate interplay between the DNA damage response pathway,PARP1 inhibition,and response of γ-calicheamicin-induced DNA damages in AML and ALL. These findings underscore the importance of targeted therapeutic strategies and pave the way for future research aimed at optimizing leukemia treatment approaches. The online version contains supplementary material available at 10.1186/s12967-024-05838-9. View Publication -
A. Montepeloso et al. (Nov 2024) Nature Communications 15Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients
Transplantation of engineered hematopoietic stem/progenitor cells (HSPCs) showed curative potential in patients affected by neurometabolic diseases treated in early stage. Favoring the engraftment and maturation of the engineered HSPCs in the central nervous system (CNS) could allow enhancing further the therapeutic potential of this approach. Here we unveil that HSPCs haplo-insufficient at the Cx3cr1 (Cx3cr1 −/+ ) locus are favored in central nervous system (CNS) engraftment and generation of microglia-like progeny cells (MLCs) as compared to wild type (Cx3cr1 +/+ ) HSPCs upon transplantation in mice. Based on this evidence,we have developed a CRISPR-based targeted gene addition strategy at the human CX3CR1 locus resulting in an enhanced ability of the edited human HSPCs to generate mature MLCs upon transplantation in immunodeficient mice,and in lineage specific,regulated and robust transgene expression. This approach,which benefits from the modulation of pathways involved in microglia maturation and migration in haplo-insufficient cells,may broaden the application of HSPC gene therapy to a larger spectrum of neurometabolic and neurodegenerative diseases. Subject terms: Targeted gene repair,Haematopoietic stem cells,Microglial cells View Publication -
T. Guo et al. (Nov 2024) Journal of Translational Medicine 22 3Isolation and identification of patient-derived liver cancer stem cells and development of personalized treatment strategies
Liver cancer stem cells (LCSCs) are thought to drive the metastasis and recurrence,however,the heterogeneity of molecular markers of LCSCs has hindered the development of effective methods to isolate them. This study introduced an effective approach to isolate and culture LCSCs from human primary liver cancer (HPLC),leveraging mouse embryonic fibroblasts (MEFs) as feeder cells in conjunction with using defined medium. Isolated LCSCs were further characterized by multiple approaches. Transcriptome sequencing data analysis was conducted to identify highly expressed genes in LCSCs and classify different subtypes of liver cancers. Total sixteen cell strains were directly isolated from 24 tissues of three types of HPLC without sorting,seven of which could be maintained long-term culture as colony growth on MEFs,which is unique characteristics of stem cells. Even 10 of cloned cells formed the tumors in immunodeficient mice,indicating that those cloned cells were tumorgenic. The histologies and gene expression pattern of human xenografts were very similar to those of HPLC where these cloned cells were isolated. Moreover,putative markers of LCSCs were further verified to all express in cloned cells,confirming that these cells were LCSCs. These cloned LCSCs could be cryopreserved,and still maintained the feature of colony growth on MEFs after the recovery. Compared to suspension culture as conventional approach to culture LCSCs,our approach much better maintained stemness of LCSCs for a long time. To date,these cloned cells could be cultured on MEFs over 12 passages. Moreover,bioinformatics analysis of sequencing data revealed the gene expression profiles in LCSCs,and liver cancers were classified into two subtypes C1 and C2 based on genes associated with the prognosis of LCSCs. Patients of the C2 subtype,which is closely related to the extracellular matrix,were found to be sensitive to treatments such as Cisplatin,Axitinib,JAK1 inhibitors,WNT-c59,Sorafenib,and RO-3306. In summary,this effective approach offers new insights into the molecular landscape of human liver cancers,and the identification of the C2 subtype and its unique response to the treatment pave the way for the creation of more effective,personalized therapeutic strategies. The online version contains supplementary material available at 10.1186/s12967-024-05870-9. View Publication -
S. Peltonen et al. (Nov 2024) Fluids and Barriers of the CNS 21 1Mutated LRRK2 induces a reactive phenotype and alters migration in human iPSC-derived pericyte-like cells
Pericytes play a crucial role in controlling inflammation and vascular functions in the central nervous system,which are disrupted in Parkinson’s disease (PD). Still,there is a lack of studies on the impact of pericytes on neurodegenerative diseases,and their involvement in the pathology of PD is unclear. Our objective was to investigate the molecular and functional differences between healthy pericytes and pericytes with the LRRK2 G2019S mutation,which is one of the most common mutations associated with PD. Our study employed pericyte-like cells obtained from induced pluripotent stem cells produced from PD patients with the LRRK2 G2019S mutation as well as from healthy individuals. We examined the gene expression profiles of the cells and analyzed how the alterations reflect on their functionality. We have shown differences in the expression of genes related to inflammation and angiogenesis. Furthermore,we observe modified migration speed in PD pericyte-like cells as well as enhanced secretion of inflammatory mediators,such as soluble VCAM-1 and MCP-1,in these pericyte-like cells following exposure to proinflammatory stimuli. In summary,our findings support the notion that pericytes play a role in the inflammatory and vascular changes observed in PD. Further investigation of pericytes could provide valuable insight into understanding the pathogenesis of PD. The online version contains supplementary material available at 10.1186/s12987-024-00592-y. View Publication -
L. D. Volpe et al. (Nov 2024) Cell Reports Medicine 5 11A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells
Ex vivo activation is a prerequisite to reaching adequate levels of gene editing by homology-directed repair (HDR) for hematopoietic stem and progenitor cell (HSPC)-based clinical applications. Here,we show that shortening culture time mitigates the p53-mediated DNA damage response to CRISPR-Cas9-induced DNA double-strand breaks,enhancing the reconstitution capacity of edited HSPCs. However,this results in lower HDR efficiency,rendering ex vivo culture necessary yet detrimental. Mechanistically,ex vivo activation triggers a multi-step process initiated by p38 mitogen-activated protein kinase (MAPK) phosphorylation,which generates mitogenic reactive oxygen species (ROS),promoting fast cell-cycle progression and subsequent proliferation-induced DNA damage. Thus,p38 inhibition before gene editing delays G1/S transition and expands transcriptionally defined HSCs,ultimately endowing edited cells with superior multi-lineage differentiation,persistence throughout serial transplantation,enhanced polyclonal repertoire,and better-preserved genome integrity. Our data identify proliferative stress as a driver of HSPC dysfunction with fundamental implications for designing more effective and safer gene correction strategies for clinical applications. View Publication -
Y. Li et al. (Nov 2024) eBioMedicine 110 5A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity
Global dissemination of SARS-CoV-2 Omicron sublineages has provided a sufficient opportunity for natural selection,thus enabling beneficial mutations to emerge. Characterisation of these mutations uncovers the underlying machinery responsible for the fast transmission of Omicron variants and guides vaccine development for combating the COVID-19 pandemic. Through systematic bioinformatics analysis of 496,606 sequences of Omicron variants,we obtained 40 amino acid substitutions that occurred with high frequency in the S protein. Utilising pseudoviruses and a trans -complementation system of SARS-CoV-2,we identified the effect of high-frequency mutations on viral infectivity and elucidated the molecular mechanisms. Finally,we evaluated the impact of a key emerging mutation on the immune protection induced by the SARS-CoV-2 VLP mRNA vaccine in a murine model. We identified a proline-to-leucine substitution at the 1263rd residue of the Spike protein,and upon investigating the relative frequencies across multiple Omicron sublineages,we found a trend of increasing frequency for P1263L. The substitution significantly enhances the capacity for S-mediated viral entry and improves the immunogenicity of a virus-like particle mRNA vaccine. Mechanistic studies showed that this mutation is located in the FERM binding motif of the cytoplasmic tail and impairs the interaction between the S protein and the Ezrin/Radixin/Moesin proteins. Additionally,this mutation facilitates the incorporation of S proteins into SARS-CoV-2 virions. This study offers mechanistic insight into the constantly increasing transmissibility of SARS-CoV-2 Omicron variants and provides a meaningful optimisation strategy for vaccine development against SARS-CoV-2. This study was supported by grants from the National Key Research and Development Plan of China (2021YFC2302405,2022YFC2303200,2021YFC2300200 and 2022YFC2303400),the National Natural Science Foundation of China (32188101,32200772,82422049,82241082,32270182,82372254,82271872,82341046,32100755 and 82102389),Shenzhen Medical Research Fund (B2404002,A2303036),the Shenzhen Bay Laboratory Startup Fund (21330111),Shenzhen San-Ming Project for Prevention and Research on Vector-borne Diseases (SZSM202211023),Yunnan Provincial Science and Technology Project at Southwest United Graduate School (202302AO370010). The New Cornerstone Science Foundation through the New Cornerstone Investigator Program,and the Xplorer Prize from Tencent Foundation. View Publication -
S. Zhang et al. (Nov 2024) Nature Cell Biology 26 12Fetch Error (529 Server Error: unknown for url: https://pmc.ncbi.nlm.nih.gov/articles/11628400)
Fetch Error (529 Server Error: unknown for url: https://pmc.ncbi.nlm.nih.gov/articles/11628400) View Publication -
H. Lee et al. (Nov 2024) Nature Communications 15Infectious parvovirus B19 circulates in the blood coated with active host protease inhibitors
The lack of a permissive cell culture system has limited high-resolution structures of parvovirus B19 (B19V) to virus-like particles (VLPs). In this study,we present the atomic resolution structure (2.2 Å) of authentic B19V purified from a patient blood sample. There are significant differences compared to non-infectious VLPs. Most strikingly,two host protease inhibitors (PIs),inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) and serpinA3,were identified in complex with the capsids in all patient samples tested. The ITIH4 binds specifically to the icosahedral fivefold axis and serpinA3 occupies the twofold axis. The protein-coated virions remain infectious,and the capsid-associated PIs retain activity; however,upon virion interaction with target cells,the PIs dissociate from the capsid prior to viral entry. Our finding of an infectious virion shielded by bound host serum proteins suggests an evolutionarily favored phenomenon to evade immune surveillance and escape host protease activity. Subject terms: Cryoelectron microscopy,Virology View Publication -
D. Kim et al. (Oct 2024) Nature Communications 15Scalable production of uniform and mature organoids in a 3D geometrically-engineered permeable membrane
The application of organoids has been limited by the lack of methods for producing uniformly mature organoids at scale. This study introduces an organoid culture platform,called UniMat,which addresses the challenges of uniformity and maturity simultaneously. UniMat is designed to not only ensure consistent organoid growth but also facilitate an unrestricted supply of soluble factors by a 3D geometrically-engineered,permeable membrane-based platform. Using UniMat,we demonstrate the scalable generation of kidney organoids with enhanced uniformity in both structure and function compared to conventional methods. Notably,kidney organoids within UniMat show improved maturation,showing increased expression of nephron transcripts,more in vivo-like cell-type balance,enhanced vascularization,and better long-term stability. Moreover,UniMat’s design offers a more standardized organoid model for disease modeling and drug testing,as demonstrated by polycystic-kidney disease and acute kidney injury modeling. In essence,UniMat presents a valuable platform for organoid technology,with potential applications in organ development,disease modeling,and drug screening. Subject terms: Nanofabrication and nanopatterning,Biomaterials,Stem-cell biotechnology View Publication -
M. Fournier et al. (Oct 2024) EMBO Molecular Medicine 16 12Reciprocal inhibition of NOTCH and SOX2 shapes tumor cell plasticity and therapeutic escape in triple-negative breast cancer
Cancer cell plasticity contributes significantly to the failure of chemo- and targeted therapies in triple-negative breast cancer (TNBC). Molecular mechanisms of therapy-induced tumor cell plasticity and associated resistance are largely unknown. Using a genome-wide CRISPR-Cas9 screen,we investigated escape mechanisms of NOTCH-driven TNBC treated with a gamma-secretase inhibitor (GSI) and identified SOX2 as a target of resistance to Notch inhibition. We describe a novel reciprocal inhibitory feedback mechanism between Notch signaling and SOX2. Specifically,Notch signaling inhibits SOX2 expression through its target genes of the HEY family,and SOX2 inhibits Notch signaling through direct interaction with RBPJ. This mechanism shapes divergent cell states with NOTCH positive TNBC being more epithelial-like,while SOX2 expression correlates with epithelial-mesenchymal transition,induces cancer stem cell features and GSI resistance. To counteract monotherapy-induced tumor relapse,we assessed GSI-paclitaxel and dasatinib-paclitaxel combination treatments in NOTCH inhibitor-sensitive and -resistant TNBC xenotransplants,respectively. These distinct preventive combinations and second-line treatment option dependent on NOTCH1 and SOX2 expression in TNBC are able to induce tumor growth control and reduce metastatic burden. View Publication -
C. Pascual-Caro et al. (Oct 2024) PLOS Biology 22 10Monitoring of activity-driven trafficking of endogenous synaptic proteins through proximity labeling
To enable transmission of information in the brain,synaptic vesicles fuse to presynaptic membranes,liberating their content and exposing transiently a myriad of vesicular transmembrane proteins. However,versatile methods for quantifying the synaptic translocation of endogenous proteins during neuronal activity remain unavailable,as the fast dynamics of synaptic vesicle cycling difficult specific isolation of trafficking proteins during such a transient surface exposure. Here,we developed a novel approach using synaptic cleft proximity labeling to capture and quantify activity-driven trafficking of endogenous synaptic proteins at the synapse. We show that accelerating cleft biotinylation times to match the fast dynamics of vesicle exocytosis allows capturing endogenous proteins transiently exposed at the synaptic surface during neural activity,enabling for the first time the study of the translocation of nearly every endogenous synaptic protein. As proof-of-concept,we further applied this technology to obtain direct evidence of the surface translocation of noncanonical trafficking proteins,such as ATG9A and NPTX1,which had been proposed to traffic during activity but for which direct proof had not yet been shown. The technological advancement presented here will facilitate future studies dissecting the molecular identity of proteins exocytosed at the synapse during activity,helping to define the molecular machinery that sustains neurotransmission in the mammalian brain. View Publication -
K. Kusaba et al. (Oct 2024) International Journal of Molecular Sciences 25 20Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia (CML) respond to tyrosine kinase inhibitors (TKIs); however,CML leukemic stem cells (LSCs) exhibit BCR::ABL kinase-independent growth and are insensitive to TKIs,leading to disease relapse. To prevent this,new therapies targeting CML-LSCs are needed. Rates of mitochondria-mediated oxidative phosphorylation (OXPHOS) in CD34 + CML cells within the primitive CML cell population are higher than those in normal undifferentiated hematopoietic cells; therefore,the inhibition of OXPHOS in CML-LSCs may be a potential cure for CML. NK-128 (C 33 H 61 NO 5 S) is a structurally simplified analog of JCI-20679,the design of which was based on annonaceous acetogenins. NK-128 exhibits antitumor activity against glioblastoma and human colon cancer cells by inhibiting OXPHOS and activating AMP-activated protein kinase (AMPK). Here,we demonstrate that NK-128 effectively suppresses the growth of CML cell lines and that the combination of imatinib and NK-128 is more potent than either alone in a CML xenograft mouse model. We also found that NK-128 inhibits colony formation by CD34 + CML cells isolated from the bone marrow of untreated CML patients. Taken together,these findings suggest that targeting OXPHOS is a beneficial approach to eliminating CML-LSCs,and may improve the treatment of CML. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 85 项目
- HLA 59 项目
- 上皮细胞生物学 270 项目
- 上皮细胞研究 3 项目
- 免疫 1032 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 38 项目
- 嵌合体 30 项目
- 干细胞生物学 2916 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 6 项目
- 新陈代谢 4 项目
- 杂交瘤制备 3 项目
- 疾病建模 206 项目
- 癌症 7 项目
- 神经科学 663 项目
- 移植研究 106 项目
- 类器官 155 项目
- 细胞外囊泡研究 8 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 101 项目
- 细胞系制备 187 项目
- 脐带血库 74 项目
- 药物发现和毒理检测 379 项目
- 血管生成细胞研究 1 项目
- 传染病 54 项目
- 内皮细胞生物学 8 项目
- 杂交瘤生成 18 项目
- 癌症研究 710 项目
- 血管生成细胞研究 57 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 10 项目
- CellShield 1 项目
- CellSTACK 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ErythroClear 3 项目
- ES-Cult 81 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- iCell 14 项目
- Matrigel 2 项目
- MegaCult 36 项目
- ProstaCult 1 项目
- STEMprep 12 项目
- ALDEFLUOR 238 项目
- AggreWell 85 项目
- ArciTect 37 项目
- BloodStor 3 项目
- BrainPhys 63 项目
- CellAdhere 2 项目
- ClonaCell 112 项目
- CloneR 8 项目
- CryoStor 75 项目
- EC-Cult 2 项目
- EasySep 894 项目
- EpiCult 21 项目
- HemaTox 4 项目
- HepatiCult 25 项目
- Hypothermosol 1 项目
- ImmunoCult 32 项目
- IntestiCult 186 项目
- Lymphoprep 10 项目
- MammoCult 45 项目
- MesenCult 153 项目
- MethoCult 509 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 372 项目
- NeuroFluor 3 项目
- PBS-MINI 6 项目
- PancreaCult 11 项目
- PneumaCult 87 项目
- RSeT 13 项目
- ReLeSR 8 项目
- RoboSep 49 项目
- RosetteSep 251 项目
- STEMdiff 165 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 29 项目
- SmartDish 1 项目
- StemSpan 252 项目
- TeSR 1547 项目
- ThawSTAR 4 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 236 项目
- CD4+ 46 项目
- CD8+ 29 项目
- CHO细胞 19 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- HUVEC细胞(人脐静脉内皮细胞) 1 项目
- NK 细胞 175 项目
- PSC衍生 43 项目
- T 细胞 452 项目
- 上皮细胞 127 项目
- 中胚层 5 项目
- 乳腺细胞 103 项目
- 先天性淋巴细胞 40 项目
- 全血 8 项目
- 其他子集 1 项目
- 其他细胞系 9 项目
- 内皮细胞 13 项目
- 内皮集落形成细胞(ECFCs) 3 项目
- 内胚层 3 项目
- 前列腺细胞 20 项目
- 单个核细胞 92 项目
- 单核细胞 191 项目
- 多能干细胞 1985 项目
- 小胶质细胞 4 项目
- 巨噬细胞 43 项目
- 巨核细胞 10 项目
- 心肌细胞 20 项目
- 成骨细胞 9 项目
- 星形胶质细胞 6 项目
- 杂交瘤细胞 97 项目
- 树突状细胞(DCs) 132 项目
- 气道细胞 4 项目
- 淋巴细胞 84 项目
- 癌细胞及细胞系 146 项目
- 癌细胞和细胞系 1 项目
- 白细胞 17 项目
- 白细胞单采样本 12 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 2 项目
- 神经元 2 项目
- 神经干/祖细胞 471 项目
- 神经细胞 16 项目
- 粒细胞及其亚群 106 项目
- 红系细胞 12 项目
- 红细胞 12 项目
- 肌源干/祖细胞 10 项目
- 肝细胞 35 项目
- 肠道细胞 90 项目
- 肾细胞 4 项目
- 肿瘤细胞 26 项目
- 胰腺细胞 16 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 101 项目
- 血小板 4 项目
- 血浆 3 项目
- 血管生成细胞 4 项目
- 调节性细胞 11 项目
- 软骨细胞 8 项目
- 造血干/祖细胞 983 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 20 项目
- 间充质干/祖细胞 204 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 4 项目
- 骨髓基质细胞 1 项目
- 骨髓间质细胞 1 项目
- 髓系细胞 147 项目
- 肾脏细胞 5 项目
- CD4+T细胞 107 项目
- CD8+T细胞 88 项目
- PSC衍生上皮细胞 30 项目
- PSC衍生中胚层 20 项目
- PSC衍生内皮细胞 12 项目
- PSC衍生内胚层 20 项目
- PSC衍生心肌细胞 21 项目
- PSC衍生神经细胞 115 项目
- PSC衍生肝细胞 11 项目
- PSC衍生造血干细胞 25 项目
- PSC衍生间充质细胞 20 项目
- 其他T细胞亚型 25 项目
- 呼吸道细胞 89 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 12 项目
- 神经元 191 项目
- 调节性T细胞 65 项目
- 骨髓瘤 5 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号